


Immuno-Oncology

JUNE 2, 2021



Date	Time	Track	Presentation Title	Speaker
2-Jun	06:00 - 07:00 AM	New Advancements in Immuno-Oncology	Dynamic live cell imaging of adherent and immune cells using CellASIC® ONIX2 microfluidic platform	Jun Park, PhD Senior Scientist, MilliporeSigma
2-Jun	06:00 - 07:00 AM	Emerging Targets for Immuno-Oncology Therapy	The Good, The Bad & The Ugly: Research solutions for key regulators of the tumor microenvironment	Josh Mahlios, Ph.D. Senior Marketing Product Manager, Miltenyi Biotec
2-Jun	07:30 - 08:30 AM	New Advancements in Immuno-Oncology	Industry Response to the Expanding Need in Immuno-Oncology for Validated Antibodies	Brian McWilliams, PhD IP/WB Manager at Fortis Life Sciences
2-Jun	07:30 - 08:30 AM		Panel Presentation: xMAP® INTELLIFLEX and Immunoassay Innovations: Tools to advance immuno-oncology research	Sigrun Badrnya, PhD Manager Product Development, Life Sciences, Thermo Fisher Scientific Wilco de Jager, PhD Sr. Field Applications Scientist, Luminex
2-Jun	09:00 - 10:00 AM	New Advancements in Immuno-Oncology	Making sense out of multiplex	Dave Mason, PhD Technical Sales Specialist, Visiopharm
2-Jun	09:00 - 10:00 AM	Emerging Targets for Immuno-Oncology Therapy	Panel Presentation: Luminex Imaging and Flow Cytometry in Immuno-Oncology	Katie Gillis Product Manager, Microcapillary Flow Cytometry, Luminex Corporation Brian E. Hall Product Manager, Image Flow Cytometry, Luminex Corporation Stephanie Brunelle, Ph.D. Product Manager, CellStream, Luminex Corporation

2-Jun	10:30 - 11:30 AM	New Advancements in Immuno-Oncology	Keynote Presentation: New Checkpoints and Biomarkers	Gordon J. Freeman, PhD Professor of Medicine, Harvard Medical School
2-Jun	12:00 - 01:00 PM	New Advancements in Immuno-Oncology	Genetically-Engineered Immuno-oncology Cell Lines and Services for Early Drug Discovery Research and Preclinical Manufacturing	Stacey Ward, PhD R&D Manager, Advanced Genetic and Cell Technologies, MilliporeSigma
2-Jun	12:00 - 01:00 PM	Emerging Targets for Immuno-Oncology Therapy	Understand the resistance mechanisms of CAR T cell therapy	Yong Gu Lee Ph.D Assistant Professor, Hanyang University, College of Pharmacy
2-Jun	01:30 - 02:30 PM	Emerging Targets for Immuno-Oncology Therapy	Keynote Presentation: Hypoxia Drives Tumor Immune Suppression and Immunotherapy Resistance	Michael A. Curran, PhD Associate Professor of Immunology, MD Anderson Cancer Center, The University of Texas
2-Jun	03:00 - 04:00 PM	Emerging Targets for Immuno-Oncology Therapy	Discover the WOLF G2 Cell Sorter, the latest in Microfluidic Gentle Cell Sorting for Immuno-Oncology Applications	Lindsey Wolf Product Manager at NanoCollect Biomedical, inc.
2-Jun	03:00 - 04:00 PM	Emerging Targets for Immuno-Oncology Therapy	Functional Evaluation of Unique Anti-PDL1 Antibodies Generated through Single Plasma B Cell Cloning on the Beacon® Platform Versus a Standard Hybridoma Approach	Neha Yevalekar Scientist II
2-Jun	04:30 - 05:30 PM	New Advancements in Immuno-Oncology	Advances in High-Throughput Drug Screening Using TrueGel3D® HTS Hydrogel 3D Cell Culture Plates	Nick Asbrock, B.S. Global Product Manager for Stem Cell and 3D Cell Culture
2-Jun	04:30 - 05:30 PM	New Advancements in Immuno-Oncology	How to get all information from your tissue sample with less complexity: An introduction to automated Multiplexing IHC and Spatial genomic analysis	Sara Milosevic, Ph.D. Sales Specialist Europe, Lunaphore Technologies
2-Jun	12:00 - 12:45 AM	Emerging Targets for Immuno-Oncology Therapy	Development of FGFR4 targeted Chimeric Antigen Receptors (CARs) for treatment of Rhabdomyosarcoma	Peter Sullivan, PhD Postdoctoral Fellow, Laboratory of Dr. Rimas Orentas, Seattle Children's Research Institute

2-Jun	12:00 - 12:45 AM	New Advancements in Immuno-Oncology	Engineering universal chimeric antigen receptors (CARs) for cancer therapy	Jason Lohmueller, Ph.D. Assistant Professor, Departments of Surgery and Immunology, University of Pittsburgh, Division of Surgical Oncology Research, UPMC Hillman Cancer Center
2-Jun	12:00 - 12:45 AM	Emerging Targets for Immuno-Oncology Therapy	EZH2 as an Actionable Therapeutic Target to Enhance Anti-Tumor Immune Response In Prostate Cancer	Leigh Ellis, Ph.D. Acting Associate Professor of Medicine, Cedars-Sinai Medical Center
2-Jun	12:00 - 12:45 AM	Emerging Targets for Immuno-Oncology Therapy	Fueling Antitumor Immunity Using Oncolytic Viruses Encoding Metabolic Modulators	Dayana Rivadeneira, PhD Research Assistant Professor, Department of Immunology University of Pittsburgh
2-Jun	12:00 - 12:45 AM	Advancing Cancer Immunotherapies to the Clinic	IDO in Melanoma..... Deserves Further Evaluation	Yousef Zakharia, MD Associate Professor of Medicine, University of Iowa
2-Jun	12:00 - 12:45 AM	Emerging Targets for Immuno-Oncology Therapy	IFNg-activated dermal lymphatic vessels restrict anti-tumor immunity	Amanda Lund, PhD Associate Professor, Ronald O. Perelman Department of Dermatology and Pathology; NYU Grossman School of Medicine Member, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health
2-Jun	12:00 - 12:45 AM	Emerging Targets for Immuno-Oncology Therapy	Interrogating mechanisms of tumor-specific T cell exhaustion and activity in pancreatic ductal adenocarcinoma	Adam Burrack, M.S., Ph.D. Researcher, University of Minnesota, Center for Immunology
2-Jun	12:00 - 12:45 AM	New Advancements in Immuno-Oncology	Rational Modifications to CAR Antigen Binding Domain Improve Sensitivity to Low-Density Target Antigens	Kole DeGolier, B.S. PhD Candidate - Fry Lab Department of Immunology University of Colorado
2-Jun	12:00 - 12:45 AM	New Advancements in Immuno-Oncology	Th17-Inducing Vaccines for the Treatment of Ovarian Cancer	Keith Knutson, PhD Professor of Immunology, Mayo Clinic
2-Jun	12:00 - 12:45 AM	New Advancements in Immuno-Oncology	Using genetically engineered preclinical models to study T cell therapy against solid tumors	Leah Schmidt, PhD Postdoctoral Fellow, Fred Hutchinson Cancer Research Center